Management ChangeApr 30, 2026, 04:37 PM
CNSP Appoints New CEO, CFO, CMO, CTO; Former CEO Departs
AI Summary
CNS Pharmaceuticals, Inc. filed an Amendment No. 1 to its 10-K to include Part III information, which was omitted from the original filing. This amendment details significant changes in the executive leadership team, including the appointment of a new CEO, CFO, CMO, and CTO in early 2026. It also provides information on the departure of the former CEO and compensation details for both former and newly appointed executives.
Key Highlights
- Rami Levin appointed CEO in January 2026 with an annual base salary of $580,000.
- Steve O’Loughlin appointed CFO in March 2026 with an annual base salary of $450,000 and 9,500 RSUs.
- Lynne Kelley appointed CMO in March 2026 with an annual base salary of $450,000 and 9,500 RSUs.
- Eric Faulkner appointed CTO in March 2026 with an annual base salary of $450,000 and 9,500 RSUs.
- John Climaco (former CEO) resigned in December 2025, receiving a $319,000 bonus and 12 months severance.
- Christopher Downs transitioned from CFO to SVP – Finance in March 2026 with an annual base salary of $350,000.
- The company filed an amended 10-K to include previously omitted Part III information (Items 10-14).